Novartis to inject $100 mn into malaria drug research
3 months ago, 17 Apr 11:46
round 90 percent of the 445,000 of malaria-related deaths occurred in Africa, but people in southeast Asia, the eastern Mediterranean, the western Pacific and the Americas are also considered at risk. In a bid to redress the disproportionate burden carried by African countries, Novartis said it would establish a strategy aimed at ensuring equitable pricing. In a statement, the company also said it would “further help expand access” to treatment for children with malaria. Novartis’s announcement came as Senegal hosted a pan-African conference this week on the fight against malaria. Deaths from malaria dropped by over 60 percent from 2000 to 2015, but because of growing resistance to available treatments and insecticides, there is a risk that the progress made so far may be slowed. “Resistance to treatment presents the biggest threat to the incredible progress that has been made in the fight against malaria in the past 20 years,” Novartis CEO Vas Narasimhan said. “We cannot afford to wait; this is why we are committing to advance the research and development of next-generation treatments,” he added.
BUENOS AIRES, Argentina, Jul 22 - EU finance chief Pierre Moscovici fired a barb at US President Donald Trump on Sunday as he called on both sides of an Kenya breaking news | Kenya news today | ...Category: business